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Abstract 
Background: The prevalence of hyperuricemia has increased dramatically during the past several decades. Studies 
indicating uric acid is an independent risk factor for hypertension did not sufficiently control for other known risk fac‑
tors. We explored this relationship in a comprehensive Chinese senior dynamic cohort.
Methods: To investigate the relationship between serum uric acid (SUA) levels and hypertension, we carried out a 
6‑year retrospective study (2006–2011) in a dynamic cohort with 3591 subjects free of hypertension. The first occasion 
of documented hypertension per subject was the index event. A Cox proportional hazards model assessed the rela‑
tionship between SUA and hypertension. Kaplan–Meier survival analysis compared incidence of hypertension among 
individuals with each SUA quartile. Receiver operating characteristic curves were generated to obtain the area under 
the curve as a prediction of hypertension from SUA levels.
Results: The cumulative prevalence of hypertension in our cohort was 20.7 %. The prevalence of hyperuricemia was 
17.5 %. Cox regression analysis showed that, compared with the lowest SUA quartile (<4.69 mg/dl), the 4.69–5.58, 
5.58–6.52, and ≥6.52 mg/dl quartiles yielded hazard ratios (95 % confidence intervals) for hypertension of 1.652 
(1.265–2.156), 2.195 (1.705–2.825), and 3.058 (2.399–3.899), respectively. Cumulative incidence of hypertension was 
consistently higher among individuals with hyperuricemia than among those with normal SUA levels. A Kaplan–Meier 
survival analysis showed that hyperuricemia predicted higher incidences of hypertension in a dose‑dependent man‑
ner: hypertension onset significantly differed across SUA quartiles. SUA levels were significantly and independently 
associated with incidence of hypertension in our cohort.
Conclusions: Our results, controlling for known risk factors, suggest that SUA level is an independent risk factor for 
hypertension and could be a useful indicator of hypertension.
Keywords: Hyperuricemia, Hypertension, Dynamic cohort study, Survival analysis
© 2016 Wei et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/




*Correspondence:  wyg@tmu.edu.cn; yangxilin@tmu.edu.cn; 
liweidong98@tijmu.edu.cn 
†Fengjiang Wei, Ning Sun, Chunyou Cai and Shuzhi Feng contributed 
equally to this paper
1 Research Center of Basic Medical Sciences, Tianjin Medical University, 22 
Qixiangtai Road, Tianjin 300070, People’s Republic of China
4 School of Public Health, Tianjin Medical University, 22 Qixiangtai Road, 
Tianjin 300070, People’s Republic of China
5 Department of Epidemiology and Biostatistics, School of Public Health, 
Tianjin Medical University, 22 Qixiangtai Road, Tianjin 300070, People’s 
Republic of China
Full list of author information is available at the end of the article
Page 2 of 9Wei et al. J Transl Med  (2016) 14:110 
Background
Uric acid is the final product of purine metabolism. 
Serum uric acid (SUA) concentration is precisely regu-
lated, including secretion and reabsorption in the kidneys. 
Hypertension is highly prevalent, affecting approximately 
one-third of Americans and is a leading cause of morbid-
ity and mortality [1]. While the etiology of hypertension is 
unclear in many patients, uric acid has been hypothesized 
to activate the renin–angiotensin system, which can lead 
to injury to prerenal blood vessels [2].
A number of epidemiological studies have shown that 
increased uric acid concentrations are associated with 
increased risk for developing hypertension [3, 4]. Some 
observations in cross-sectional analyses and longitudinal 
studies concluded there was a hyperuricemia-hyperten-
sion link [5–9]. Although elevated SUA levels have been 
predictive of hypertension in longitudinal studies, the 
relationship between uric acid and blood pressure is con-
founded by numerous factors, so controversy remains. 
For example, although elevated uric acid levels are often 
associated with established traditional cardiovascular risk 
factors, it is not quite clear whether uric acid is the cause 
or a consequence of hypertension; studies indicating uric 
acid as an independent risk factor did not sufficiently 
control for other known risk factors; thus, how uric acid 
causes hypertension is not fully understood [10].
To decipher the relationship between SUA and hyper-
tension while controlling for known risk factors, includ-
ing sex, BMI, eGFR, and several metabolic factors, we 
collected a dynamic cohort comprising primarily senior 
citizens (the Tianjin General Hospital cohort) in the city 
of Tianjin, China, and performed physical exams and 
clinical/biochemical tests each year from 2006 to 2011.
Methods
Subjects
We recruited 7032 subjects for this study from 2006 to 
2011. Recruited subjects were asked to participate in an 
annual physical examination up to 2011. At their entry 
examinations, a total of 3441 subjects were found to 
have hypertension, and during the follow-up period, 744 
out of the remaining 3591 subjects developed incident 
hypertension. We organized two studies: (1) a cross-sec-
tional survey using the data at the study entry; and (2) a 
dynamic cohort study of the subjects who did not have 
hypertension at study entry. Subject recruiting proto-
cols were reviewed and approved by the Human Ethics 
Committee of Tianjin Medical University. Subjects gave 
informed consent prior to participating in this study. All 
experiments were performed in accordance with relevant 
guidelines and regulations.
All of the subjects who were randomly assigned were 
eligible for this study provided they met all following 
criteria at the baseline: (1) no evidence of hypertension 
(defined as systolic blood pressure of ≥140 mmHg and/
or a diastolic blood pressure of ≥90 mmHg, and/or the 
current use of antihypertensive medication, regardless of 
the recorded blood pressure); (2) no evidence of left ven-
tricular hypertrophy/myocardial infarction/heart failure; 
(3) no evidence of diabetes mellitus (defined as a fasting 
plasma glucose ≥126 mg/dl (7.0 mmol/L), or the use of 
antidiabetic medications); (4) no evidence of kidney dis-
ease or gout, and no use of diuretics/allopurinol to lower 
uric acid levels; (5) availability of serum uric acid meas-
urement at baseline or the follow-up examinations; and 
(6) availability of blood pressure at baseline or follow-up 
examinations.
Annual physical exams
At each exam, all subjects were measured twice for 
height and weight (using identical standardized anthro-
pometric scales), and body mass index (BMI) was calcu-
lated as body weight (kg) divided by height squared (m2). 
A well-trained nurse or doctor measured resting blood 
pressure once using a standard mercury sphygmoma-
nometer with the subject in the sitting position after at 
least 5 min of rest. All the subjects fasted overnight for at 
least 12 h before blood sampling. Venous blood samples 
were obtained from the antecubital vein for measuring 
SUA levels (Additional file  1: Tables S1 and S2), fasting 
glucose, lipid profiles (total cholesterol, triglycerides), 
renal function (plasma creatinine, blood urea nitrogen), 
liver function (total serum protein, albumin, globulin, 
total and direct bilirubin, and aspartate aminotrans-
ferase), white cell count, hemoglobin tests. SUA levels 
were measured by enzymatic methods (Chemistry Ana-
lyzer Au2700, Olympus Medical Engineering Company, 
Japan). Newly diagnosed diseases during the past year 
and identified at the physical exam were documented.
Definitions
Hypertension was defined as a systolic blood pres-
sure of ≥140  mmHg and/or a diastolic blood pressure 
of ≥90  mmHg, and/or the current use of antihyperten-
sive medication. For calculating incidence rates, we used 
the first occasion of documented hypertension per sub-
ject as the index event. According to the recommended 
criteria for the Chinese people [11], normal weight was 
defined as a BMI of 18.5–23.9  kg/m2, overweight as a 
BMI of 24.0–27.9 kg/m2, and obesity as a BMI ≥ 28 kg/
m2. Values of estimated glomerular filtration rate (eGFR; 
ml/min/1.73  m2) were calculated using the equation 
proposed by investigators in the Chronic Kidney Dis-
ease Epidemiology Collaboration. Hyperuricemia was 
defined as SUA ≥ 7.0 mg/dL (420 μmol/L) in males and 
≥6.0  mg/dL (360  μmol/L) in females. SUA levels were 
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categorized by quartiles as <4.69, 4.69–5.58, 5.58–6.52, 
and ≥6.52 mg/dl.
In this paper, the data are divided into three groups: (1) 
baseline data from subjects who did not have hyperten-
sion at the study entry; (2) follow-up means calculated 
from specified observations starting from the time of the 
baseline visit through the last follow-up visit or first occa-
sion of hypertension (index event); and (3) normal-eGFR 
subjects with eGFR ≥ 60 ml/min/1.73 m2 (chronic kidney 
disease was defined as eGFR < 60 ml/min/1.73 m2) [12].
Data analysis
The basic characteristics of the sample are described 
by descriptive statistics. The data for continuous varia-
bles are reported as the mean ± SD and median (inter-
quartile range), and the data for categorical variables 
are reported as percentages (%). The clinical charac-
teristics between nonhypertensive and hypertensive 
groups were analyzed using the Student’s t test for 
data that were normally distributed, and the Mann–
Whitney U-test for non-normal distributions, The 
Table 1 Characteristics of subjects [mean ± SD or N (%)] during baseline and follow-up periodsa by status at follow-up 
(hypertensive, nonhypertensive)
BMI body mass index; TG plasma levels of triglycerides; TC total cholesterol; HDL high-density lipoprotein; eGFR estimated glomerular filtration rate; SUA serum uric 
acid; BUN blood urea nitrogen; SCR serum creatinine; SBP systolic blood pressure; DBP diastolic blood pressure; FBG fasting plasma glucose; TP plasma total protein; 
GLB globulin; ALB albumin; ALT alanine aminotransferase; TBIL total bilirubin; DBIL direct bilirubin
a Means during the follow-up period are specified observations starting from the time of the baseline visit through the last visit or incidence of hypertension







Baseline Follow-up Baseline Follow-up Baseline Follow-up
Male (%) 570 (76.61 %) 1980 (69.55 %) 0.000 0.000
Female (%) 174 (23.39 %) 867 (30.45 %)
Age (years) 61.47 ± 11.66 63.82 ± 11.63 55.61 ± 13.41 56.64 ± 13.33 0.000 0.000
BMI (kg/m2) 24.85 ± 3.04 24.76 ± 2.92 24.06 ± 3.03 24.01 ± 3.00 0.000 0.000
Overweight (BMI = 24–27.9 kg/m2) 350 (47.0 %) 346 (46.5 %) 1115 (40.5 %) 1130 (39.7 %) – –
Obese (BMI ≥ 28 kg/m2) 105 (14.1 %) 96 (12.9 %) 268 (9.4 %) 253 (8.9 %) – –
TG (mg/dl) 148.85 ± 95.69 149.73 ± 82.40 131.13 ± 95.69 134.67 ± 93.05 0.000 0.000
TC (mg/dl) 188.27 ± 32.47 189.82 ± 30.54 186.34 ± 32.47 186.73 ± 30.54 0.165 0.023
HDL (mg/dl) 51.80 ± 15.46 51.03 ± 14.69 53.35 ± 15.46 53.35 ± 15.46 0.059 0.000
eGFR (ml/min/1.73 m2) 86.96 ± 17.03 86.62 ± 15.69 90.51 ± 18.15 91.31 ± 22.62 0.000 0.000
≥60 (ml/min/1.73 m2) 711 (95.6 %) 712 (95.7 %) 2727 (95.8 %) 2738 (96.2 %) – –
<60 (ml/min/1.73 m2) 33 (4.4 %) 32 (4.3 %) 120 (4.2 %) 109 (3.8 %) – –
SUA (mg/dl) 6.26 ± 1.38 5.65 ± 1.20 5.50 ± 1.33 5.47 ± 1.27 0.000 0.000
BUN (mg/dl) 15.41 ± 3.53 15.49 ± 2.97 14.54 ± 3.53 14.57 ± 3.36 0.000 0.000
SCR (mg/dl) 0.92 ± 0.21 0.91 ± 0.18 0.88 ± 0.18 0.88 ± 0.17 0.000 0.000
SBP (mmHg) 140 140 119.62 ± 10.97 119.60 ± 10.46 0.000 0.000
DBP (mmHg) 90 90 70.01 ± 8.83 69.59 ± 8.41 0.000 0.000
FBG (mg/dl) 92.44 ± 22.71 98.93 ± 21.26 92.08 ± 18.02 94.42 ± 16.58 0.682 0.000
TP (g/L) 75.28 ± 4.06 74.69 ± 3.51 82.38 ± 10.83 73.68 ± 3.68 0.000 0.000
GLB (g/L) 29.66 ± 3.36 29.56 ± 3.07 28.27 ± 3.42 28.15 ± 3.27 0.000 0.000
ALB (g/L) 45.62 ± 2.61 45.12 ± 2.14 45.67 ± 2.70 45.52 ± 2.51 0.641 0.000
ALT (IU/L) 28.63 ± 22.08 25.25 ± 12.29 23.26 ± 17.98 22.19 ± 11.90 0.000 0.000
TBIL (mg/dl) 0.82 ± 0.29 0.90 ± 0.29 0.82 ± 0.31 0.84 ± 0.29 0.265 0.000
DBIL mg/dl) 0.12 ± 0.07 0.17 ± 0.10 0.19 ± 0.11 0.20 ± 0.09 0.000 0.000
Hypertension incidence (2007–2011)
 2006 n/incidence (baseline/follow‑up) 0/0.00 % (932/821)
 2007 n/incidence (baseline/follow‑up) 155/9.15 % (1694/1567)
 2008 n/incidence (baseline/follow‑up) 191/11.27 % (1695/1636)
 2009 n/incidence (baseline/follow‑up) 157/8.92 % (1761/1683)
 2010 n/incidence (baseline/follow‑up) 122/6.89 % (1770/1615)
 2011 n/incidence (baseline/follow‑up) 119/5.73 % (2077/2077)
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Chi squared test was used to compare differences in 
percentages in the dichotomous variables. A Cox pro-
portional hazards model was used to assess the rela-
tionship between SUA and hypertension; hazard ratios 
and 95  % confidence intervals (CIs) for hypertension 
were calculated. Kaplan–Meier survival analysis was 
used to compare incidence of hypertension among 
individuals with each SUA quartile. The log rank test 
was used to compare the curves. Receiver operating 
characteristic (ROC) curves were generated to obtain 
the area under the curve (AUC) as a prediction of 
hypertension from SUA levels. Status for hyperten-
sion, myocardial infarction, stroke, type 1 and type 2 
diabetes, and 45 other diseases was documented in a 
Filemaker Pro database. For statistical inference, a 
bilateral P-value of <0.05 was considered statistically 
significant. All statistical analyses were carried out 
using SPSS statistical software, version 17.0 (SPSS Inc., 
Chicago, IL, USA) for Windows.
Results
In our dynamic cohort study, 3591 individu-
als were included; the mean age of the subjects was 
56.83 ± 13.28 years, with 2550 males (71.0 %; mean ± SD, 
59.82  ±  13.30  years of age) and 1041 females (29.0; 
57.27  ±  13.02  years of age). The characteristics of the 
subjects at baseline and during the follow-up period are 
shown in Tables 1 and 2. BMI, age, most blood measures, 
and the prevalence of male sex and obesity increased in 
the hypertensive group, but eGFR and direct bilirubin 
levels significantly decreased. After 6  years, cumulative 
prevalence of hypertension was 20.7 % (22.4 % in males, 
16.7 % in females; χ2 = 14.307, P < 0.001). The prevalence 
of hyperuricemia was 17.5 % (19.9 % in males, 11.7 % in 
females; χ2 =  33.942, P  <  0.001). A cross-sectional sur-
vey was organized using baseline data from 3591 subjects 
enrolled. Logistic regression analysis identified SUA level 
as a factor that increased hypertension risk (Table 3). In 
an unadjusted model odds ratio (95 % CIs) for hyperten-
sion, compared with the lowest SUA quartile (<4.69 mg/
dl), the 4.69–5.58, 5.58–6.52, and ≥6.52 mg/dl quartiles 
yielded odds ratios (95 % confidence intervals) for hyper-
tension of 1.989 (1.497–2.644), 2.975 (2.267–3.905), and 
4.684 (3.596–6.102), respectively. After controlling for 
confounders, in adjusted models (models 2 and 3) the dif-
ference remained, and risk of hypertension was higher as 
SUA levels increased.
We conduct a dynamic cohort study of the subjects 
who did not have hypertension at the study entry. A Cox 
proportional hazards model was used to assess the rela-
tionship between SUA and hypertension. At baseline, 
in an unadjusted model (Table  4, model 1) the hazard 
ratios (95  % CIs) for hypertension in the second, third, 
and fourth SUA quartiles, compared with the first SUA 
quartile, were 1.652 (95  % CI 1.265–2.156), 2.195 (95  % 
CI 1.705–2.825), and 3.058 (95  % CI 2.399–3.899), 
respectively; after adjusting for age and sex (model 2), 
they were 1.644 (95  % CI 1.253–2.158), 2.274 (95  % CI 
1.746–2.963), and 3.174 (95  % CI 2.448–4.114), respec-
tively. The association was also significant after further 
adjustment for multiple metabolic parameters (model 3): 
the hazard ratios comparing the second, third, and fourth 
SUA quartiles versus first SUA quartile were 1.745 (95 % 
CI 1.321–2.328), 2.349 (95 % CI 1.774–3.111), and 3.152 
(95 % CI 2.371–4.191), respectively (P < 0.001). When the 
analyses were repeated using SUA levels as a continuous 
variable, significant associations were observed in mod-
els 1–3 between increased SUA levels (1 μmol/L) and the 
risk of hypertension.
When we used means for subject characteristics dur-
ing the follow-up period, in unadjusted models (Table 4, 
model 4), significant differences were identified in 
the second and fourth SUA quartile, but not the third 
quartile, compared with the first. After controlling for 
confounders, in adjusted models (models 5 and 6) the dif-
ference remained, and risk of hypertension was higher in 
the second and fourth SUA quartiles.
Table 2 Correlation analyses among serum uric acid levels 
and  clinical characteristics during  baseline and  follow-up 
periods
BMI body mass index; TG plasma levels of triglycerides; TC total cholesterol; HDL 
high-density lipoprotein; eGFR estimated glomerular filtration rate; SUA serum 
uric acid; BUN blood urea nitrogen; SCR serum creatinine; SBP systolic blood 
pressure; DBP diastolic blood pressure; FBG fasting plasma glucose; TP plasma 
total protein; GLB globulin; ALB albumin; ALT alanine aminotransferase; TBIL total 
bilirubin; DBIL direct bilirubin
Characteristic Baseline Follow-up
R P r P
Age (years) 0.044 0.009 0.024 0.151
BMI (kg/m2) 0.340 0.000 0.362 0.000
TG (mg/dl) 0.262 0.000 0.297 0.000
TC (mg/dl) 0.023 0.278 0.013 0.509
HDL (mg/dl) −0.232 0.000 −0.311 0.000
eGFR (ml/min/1.73 m2) −0.236 0.000 −0.195 0.000
BUN (mg/dl) 0.192 0.000 0.222 0.000
SCR (mg/dl) 0.435 0.000 0.485 0.000
SBP (mmHg) 0.171 0.000 0.165 0.000
DBP (mmHg) 0.189 0.000 0.201 0.000
FBG (mg/dl) 0.023 0.162 0.046 0.006
TP (g/L) −0.092 0.000 0.088 0.000
GLB (g/L) 0.056 0.001 0.023 0.175
ALB (g/L) 0.080 0.000 0.105 0.000
ALT (IU/L) 0.136 0.000 0.223 0.000
TBIL (mg/dl) 0.140 0.000 0.159 0.000
DBIL (mg/dl) −0.022 0.192 0.067 0.000
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To investigate effects of impaired renal function on 
uric acid phenotype correlations, we divided our cohort 
by normal (≥60 ml/min/1.73 m2) and abnormal (<60 ml/
min/1.73  m2) eGFR. The Cox regression results in nor-
mal-eGFR subjects were relatively unchanged (Table  5). 
In an unadjusted model (model A), the hazard ratios 
(95  % CIs) for hypertension in the second, third, and 
fourth SUA quartiles, compared with the first SUA quar-
tile, were 1.738 (95  % CI 1.321–2.287), 2.166 (95  % CI 
1.666–2.815), and 3.065 (95  % CI 2.386–3.937), respec-
tively. After adjusting for age and sex (model B), they 
were 1.761 (95 % CI 1.331–2.329), 2.305 (95 % CI 1.751–
3.035), and 3.320 (95  % CI 2.535–4.347), respectively. 
After further adjustment for multiple metabolic param-
eters (model C), they were 1.662 (95 % CI 1.261–2.190), 
2.028 (95 % CI 1.552–2.649), and 2.747 (95 % CI 2.115–
3.566), respectively (P < 0.001).
Survival analyses for hypertension status in uric acid 
quartiles during the 6-year period (2006–2011) showed 
significant dose effects in each quartile. A Kaplan–Meier 
survival analysis showed that hyperuricemia predicted 
higher incidences of hypertension in a dose-dependent 
manner: hypertension onsets significantly differed across 
SUA quartiles (Fig. 1a, b).
Because SUA level is considered as an index of renal 
function, we divided subjects by eGFR and reexamined 
the correlations. We found that most correlations 
between SUA and hypertension and liver function phe-
notypes remained essentially unchanged in the normal-
eGFR group (Table 5; Fig. 1c).
Receiver operating characteristic curves were generated 
to obtain the AUC as a prediction of hypertension from 
SUA levels. ROC analysis revealed an AUC of 0.659 in 
the ability of SUA levels to predict hypertension diagnosis 
in the total data. This model was also found to be signifi-
cantly different than the random predictor (AUC = 0.500, 
P  <  0.001). The sensitivity and specificity were 65.1 and 
58.8 %, respectively. For men, the sensitivity and specificity 
were 71.6 and 49.7 %, respectively, and the AUC was 0.647. 
For women, the sensitivity and specificity were 70.1 and 
59.8 %, respectively, and the AUC was 0.683 (Fig. 2a–c).
Discussion
In a Chinese senior dynamic cohort (the Tianjin Gen-
eral Hospital cohort), we found a significant association 
between higher SUA concentrations and an increased 
hazard of incident hypertension. This association was 
independent of age, sex, BMI, triglycerides, eGFR, 
blood urea nitrogen, serum creatinine, plasma total 
protein, globulin, alanine aminotransferase, and direct 
bilirubin. Using SUA measurements as a continuous 
measure or a dichotomous variable did not change 
Table 3 Odds ratio of SUA levels for incidence hypertension in a cross sectional survey of 3591 subjects
Quartiles based on serum uric acid levels: 1, <4.69 mg/dl; 2, 4.69–5.58 mg/dl; 3, 5.58–6.52 mg/dl; 4, ≥6.52 mg/dl
Model 3 was further adjusted for BMI, triglycerides, eGFR, blood urea nitrogen, serum creatinine, plasma total protein, globulin, alanine aminotransferase, and direct 
bilirubin
P < 0.05 was considered statistically significant
Model N (%) Odds ratio 95 % CI P-value
Model 1: unadjusted baseline values of variables
 Quartile 1 903 (25.1 %) – – 0.000
 Quartile 2 886 (24.7 %) 1.989 1.497–2.644 0.000
 Quartile 3 905 (25.2 %) 2.975 2.267–3.905 0.000
 Quartile 4 897 (25.0 %) 4.684 3.596–6.102 0.000
 SUA as a continuous variable (μmol/L) 3591 1.252 1.103–1.454 0.000
Model 2: model 1 adjusted for age and gender
 Quartile 1 – – – 0.000
 Quartile 2 – 2.107 1.568–2.833 0.000
 Quartile 3 – 3.432 2.558–4.604 0.000
 Quartile 4 – 5.492 4.091–7.372 0.000
 SUA as a continuous variable (μmol/L) – 1.298 1.047–1.609 0.017
Model 3: model 2 further adjusted for other confounders
 Quartile 1 – – – 0.000
 Quartile 2 – 2.141 1.534–2.987 0.000
 Quartile 3 – 3.213 2.288–4.511 0.000
 Quartile 4 – 5.624 3.936–8.037 0.000
 SUA as a continuous variable (μmol/L) – 1.686 1.245–2.283 0.001
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our findings. There were consistent findings across the 
various adjusted and unadjusted analyses. These results 
demonstrate that SUA level is a durable marker of risk 
for hypertension. The relative risk of hypertension 
increased in a dose-dependent manner with increasing 
uric acid quartiles.
Table 4 Hazard ratios of  SUA levels for  incidence hypertension during  6  years of  follow-up among  3591subjects with-
out hypertension at the entyry examination
Model 1–3 (Baseline) Quartiles based on serum uric acid levels: 1, <4.69 mg/dl; 2, 4.69–5.58 mg/dl; 3, 5.58–6.52 mg/dl; 4, ≥6.52 mg/dl
Model 4–6 (Means during follow-up period) Quartiles based on serum uric acid levels: 1, <4.64 mg/dl; 2, 4.64–5.41 mg/dl; 3, 5.41–5.78 mg/dl; 4, ≥5.78 mg/dl
Model 3 was further adjusted for BMI, triglycerides, eGFR, blood urea nitrogen, serum creatinine, plasma total protein, globulin, alanine aminotransferase, and direct 
bilirubin
Model 6 was further adjusted for BMI, triglycerides, total cholesterol, high-density lipoproteins, estimated glomerular filtration rate, blood urea nitrogen, serum 
creatinine, fasting plasma glucose, plasma total protein, globulin, albumin, alanine aminotransferase, total bilirubin, and direct bilirubin
* P < 0.05 was considered statistically significant
Model N (%) Hazard ratio 95 % CI P-value
Baseline values: models 1–3
Model 1: unadjusted baseline values of variables
 Quartile 1 903 (25.1 %) – – 0.000
 Quartile 2 886 (24.7 %) 1.652 1.265–2.156 0.000
 Quartile 3 905 (25.2 %) 2.195 1.705–2.825 0.000
 Quartile 4 897 (25.0 %) 3.058 2.399–3.899 0.000
 SUA as a continuous variable (μmol/L) 3591 2.039 1.747–2.379 0.000
Model 2: model 1 adjusted for age and gender
 Quartile 1 – – – 0.000
 Quartile 2 – 1.644 1.253–2.158 0.000
 Quartile 3 – 2.274 1.746–2.963 0.000
 Quartile 4 – 3.174 2.448–4.114 0.000
 SUA as a continuous variable (μmol/L) – 1.703 1.292–2.243 0.000
Model 3: model 2 further adjusted for other confounders
 Quartile 1 – – – 0.000
 Quartile 2 – 1.754 1.321–2.328 0.000
 Quartile 3 – 2.349 1.774–3.111 0.000
 Quartile 4 – 3.152 2.371–4.191 0.000
 SUA as a continuous variable (μmol/L) – 1.793 1.512–2.126 0.000
Follow‑up values: models 4–6
Model 4: unadjusted follow‑up values of variables
 Quartile 1 897 (25.0 %) – – 0.018
 Quartile 2 878 (24.5 %) 1.279 1.029–1.590 0.027
 Quartile 3 917(25.5 %) 1.160 0.886–1.519 0.281
 Quartile 4 899(25.0 %) 1.366 1.120–1.666 0.002*
 SUA as a continuous variable (μmol/L) 3591 1.104 1.030–1.184 0.005*
Model 5: model 4 adjusted for age and sex
 Quartile 1 – – – 0.009*
 Quartile 2 – 1.243 1.060–1.639 0.013*
 Quartile 3 – 1.410 0.947–1.630 0.117
 Quartile 4 – 1.264 1.155–1.722 0.001*
 SUA as a continuous variable (μmol/L) – 1.264 1.198–1.335 0.000
Model 6: model 5 further adjusted for other confounders
 Quartile 1 – – – 0.026*
 Quartile 2 – 1.103 1.031–1.179 0.004*
 Quartile 3 – 1.043 0.778–1.398 0.780
 Quartile 4 – 1.350 1.106–1.648 0.003*
 SUA as a continuous variable (μmol/L) – 1.157 1.066–1.255 0.001*
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Our findings relating SUA to hypertension incidence 
with short-term follow-up (up to 5 years) confirm several 
previous reports. Our results are similar to observations 
in cross-sectional analyses and longitudinal studies [5–7], 
and several studies report linear hazard ratios comparable 
to ours [8–14]. In the Multiple Risk Factor Intervention 
Trial (MRFIT) study [8] and the Beaver Dam study [9] the 
hazard ratios for hypertension were 1.02 and 1.31, respec-
tively. Our reported hazard ratios are larger than those 
in the MRFIT study but smaller than in the Beaver Dam 
study. In our cohort, the cumulative prevalence of hyper-
tension was 20.7  % (22.4  % in men, 16.7  % in women). 
Zhang et  al. reported prevalences of hypertension as 
19.0 % in men and 11.0 % in women in a Chinese commu-
nity [14], and Sundström et al. [15] reported a hyperten-
sion prevalence of 13.8 %. Compared with these previous 
studies, our cohort had a high cumulative incidence of 
hypertension, and the cause of this difference might be 
our older study population. The prevalence of hyperten-
sion was somewhat different from the general population 
in China. Qi et al. [16] reported that the adjusted preva-
lence of hypertension was 20.9 %, which is very close to 
ours, but Yang et al. [17] reported a higher prevalence of 
30.8 % in northeastern China by a cross-sectional study.
The survival analysis showed that hyperuricemia pre-
dicted higher incidences of hypertension in a dose-
dependent manner: hypertension onset significantly 
differed across SUA quartiles, a result consistent with that 
of Masuo et  al. [18]. Despite higher hazard ratios in the 
top quartile for SUA, in our dynamic cohort the SUA lev-
els dropped across all quartiles over the follow-up period. 
These results are somewhat contradictory to previous lon-
gitudinal studies [9, 10]. The disparity may be due to three 
main reasons. First, in the present study, we did not assess 
lifestyle-related variables such as smoking, alcohol, physi-
cal training, and eating habits, which may have affected 
SUA levels during the follow-up period. Second, there is 
known variation in SUA level when measured repeatedly, 
and because several drugs that may also have affected 
SUA levels were not assessed, we could not pursue this 
question. The last reason may result from our dynamic 
cohort: as new, younger subjects joined the cohort and 
older subjects were lost to follow-up, our results may be 
partially due to the younger age of more recent subjects.
Our study had strengths and limitations. A strength 
of our study is that the cross-sectional study and the 
dynamic cohort study generated consistent results. How-
ever, one limitation was that we did not collect data on 
lifestyle factors and socioeconomic status, which are 
known to vary in risk of hypertension [19, 20]. Despite 
this, the association between SUA and hypertension is 
unlikely mediated by these factors, and undiagnosed high 
SUA is less likely to cause changes in lifestyle and socio-
economic status. Another limitation was that the subjects 
were “healthy persons” who had routine health exami-
nations but were not patients who sought medical care. 
Table 5 Incidence of hypertension by serum uric acid quartile in normal-eGFR subjects
Model C was further adjusted for BMI, TG, eGFR, blood urea nitrogen, serum creatinine, plasma total protein, globulin, alanine aminotransferase, and direct bilirubin
Quartiles based on serum uric acid levels: 1, <4.66 mg/dl; 2, 4.66–5.53 mg/dl; 3, 5.53–6.46 mg/dl; 4, ≥6.46 mg/dl
Model N (%) Hazard ratio 95 % CI P-value
Model A: unadjusted
 Quartile 1 844 (24.5 %) – – 0.000
 Quartile 2 872 (25.4 %) 1.738 1.321–2.287 0.000
 Quartile 3 855 (24.9 %) 2.166 1.666–2.815 0.000
 Quartile 4 867 (25.2 %) 3.065 2.386–3.937 0.000
 SUA as a continuous variable (μmol/L) 3438 2.061 1.758–2.416 0.000
Model B: model A adjusted for age and sex
 Quartile 1 – – – 0.000
 Quartile 2 – 1.761 1.331–2.329 0.000
 Quartile 3 – 2.305 1.751–3.035 0.000
 Quartile 4 – 3.320 2.535–4.347 0.000
 SUA as a continuous variable (μmol/L) – 2.040 1.739–2.392 0.000
Model C: model B further adjusted for other confounders
 Quartile 1 – – – 0.000
 Quartile 2 – 1.662 1.261–2.190 0.000
 Quartile 3 – 2.028 1.552–2.649 0.000
 Quartile 4 – 2.747 2.115–3.566 0.000
 SUA as a continuous variable (μmol/L) – 1.807 1.519–2.150 0.000
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Fig. 1 Kaplan‑Meier curves for hypertension among quartiles 
of serum uric acid (SUA) levels. Baseline quartiles of SUA were 
defined as follows: first quartile, <4.69 mg/dl (<P25); second quartile, 
4.69–5.58 mg/dl (P25~); third quartile, 5.58–6.52 mg/dl (P50~); and 
fourth quartile, ≥6.52 mg/dl (≥P75). a Baseline, all subjects (log‑rank 
test P‑value <0.01, <P25 vs. other quartiles). b Follow‑up, all subjects 
(log‑rank test P‑value <0.05, <P25 vs. other quartiles). c Baseline, 
normal‑eGFR subjects only (log‑rank test P‑value <0.01, <P25 vs. other 
quartiles)
Fig. 2 Receiver operating characteristic curve for the prediction of 
hypertension from serum uric acid levels in total data [a; area under 
the curve (AUC) = 0.659], in men (b; AUC = 0.647), and in women (c; 
AUC = 0.683)
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The hospital was a top tertiary care center, and persons 
who had annual health examinations at this hospital were 
likely to civil servants, university teachers, and employees 
of government-funded agencies—persons of high socio-
economic status. Thus, they are not representative of the 
general population. Further replication our findings in 
general population is warranted, especially among sub-
jects with low socioeconomic status.
Conclusions
We found that SUA levels predicted incident hyperten-
sion in a Chinese cohort of senior persons. Increased 
SUA levels were significantly and independently asso-
ciated with the incidence of hypertension over a 6-year 
period in a dynamic cohort without hypertension at 
baseline. A survival analysis showed that elevated SUA 
levels predicted higher cumulative incidence of hyperten-
sion. To prevent cardiovascular events, this relationship 
between increased SUA levels and increased incidence 
of hypertension should be noted. In future research, we 
plan to investigate clinical outcomes of individuals with 
elevated SUA levels in our cohort and test genetic back-
grounds related to hyperuricemia in general populations.
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